SCHEMBL8937327

SCHEMBL8937327

COc1ccc(-c2cccc(C=CC(=O)O)c2)cc1OC

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.70
ALDH1A1 P00352 2/20 0.70
HPGD P15428 2/20 0.70
HSD17B10 Q99714 2/20 0.70
SMN1; SMN2 Q16637 2/20 0.70
ALOX15 P16050 1/20 0.70
MAPK1 P28482 1/20 0.70
ABCB1 P08183 1/20 0.58
SNCA P37840 2/20 0.56
PKM P14618 2/20 0.55
CA12 O43570 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA3 P07451 1/20 0.55
CSNK2A2 P19784 1/20 0.55
CA4 P22748 1/20 0.55
CA6 P23280 1/20 0.55
CA5A P35218 1/20 0.55
CA7 P43166 1/20 0.55
CSNK2B P67870 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937324 1.00 KDM4E (0.70) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL8937421 1.00 KDM4E (0.70) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL8937301 0.90 KDM4E (0.60) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL8937431 0.90 KDM4E (0.60) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL8937305 0.90 KDM4E (0.60) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL27684124 0.90 KDM4E (0.59) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL8937290 0.88 KDM4E (0.76) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL8937454 0.88 KDM4E (0.76) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL8937281 0.88 KDM4E (0.76) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL8937480 0.87 KDM4E (0.66) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP disclosed